Plain-English translation of NCT06209580 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This is a clinical trial testing a new medication called AMT-253 in people with advanced melanoma or other solid tumors that have spread or cannot be surgically removed. The trial is designed in two phases: first, researchers will test increasing doses of the medication to find the safest and most effective dose; then, they will study how well the medication works at that dose in more patients.
Standard cancer treatments have stopped working for the patients in this trial, and there are no other approved options available to them. This trial exists to see whether this new medication might offer hope for people in this situation.
You likely qualify if…
You likely don't qualify if…
You will receive the experimental medication AMT-253 as part of this multi-center study. In the first phase, doses will be gradually increased to find the safest level; in the second phase, more patients will receive the medication at the dose found to be effective. You will need to provide a tissue sample from your tumor at the start, attend regular study visits to be monitored for side effects and treatment response, and have your tumors measured with imaging scans to see if the medication is working. The trial will involve multiple visits over time, though the exact duration is not specified in this summary.
AI-generated summary from trial data · Jun 15, 2026 · Not medical advice
China
Phase
Safety & dosing / Early efficacy
Sponsor
Multitude Therapeutics Inc.
Enrollment target
~96 participants
Started
January 2024
Primary completion
April 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in September 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Minqi Guan
Multitude Therapeutics Inc.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.